Ouro Fino Saúde Animal Participações (OFSA3) Q3 2025 earnings summary

Executive summary

• Net revenue grew 26.2% year-over-year to R$356.5 million in 3Q25 and 18.7% to R$805.3 million for the nine-month period, driven by portfolio diversification, innovation, and new product launches.

• Adjusted EBITDA increased 30.6% to R$97.6 million in 3Q25 and 20.1% to R$166.0 million for 9M25.

• Recognized with the 2025 FINEP Innovation Award for the Southeast region and sustainable agroindustrial chains, highlighting robust R&D and sustainability efforts.

• Launched 8 new products in the last 12 months, including LeanVac, Safesui Glasser One, Nexlaner, and Wellpet, expanding market reach.

• Completed the merger of Ouro Fino Agronegócio Ltda. on October 1, 2025, consolidating assets and liabilities.

Financial highlights

• Gross profit rose 22.1% year-over-year in 3Q25 to R$188.3 million; nine-month gross profit was R$413.5 million (+20.0%).

• Adjusted net income increased 29.3% to R$54.8 million in 3Q25; nine-month adjusted net income was R$80.7 million (+14.0%).

• Adjusted EBITDA margin reached 27.4% in 3Q25 (+1.0 p.p. YoY); nine-month margin at 20.6%.

• Net cash generation reached R$32.5 million in 9M25, with cash and cash equivalents at R$206.6 million at period end.

• Gross debt increased to R$496.6 million, mainly due to inventory build-up and capital reduction.

Outlook and guidance

• Continued focus on innovation, R&D investment, and expanding product portfolio to drive sustainable growth and value creation.

• Fourth quarter expected to benefit from recent product launches and continued growth momentum.

• Capital reduction of R$120.1 million executed to align with value creation strategy, without compromising growth or investment capacity.